<DOC>
	<DOCNO>NCT01413204</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety TA-7284 monotherapy patient type 2 Diabetes 24 week administration .</brief_summary>
	<brief_title>Efficacy Safety Study TA-7284 Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This randomize , 3-arm , parallel group , double blind study evaluate efficacy safety TA-7284 Japanese patient Type 2 diabetes mellitus , optimally control diet exercise . The patient receive either TA-7284-Low , TA-7284-High Placebo orally alone 24 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Men woman age ≥20 year old Diagnosed Type 2 diabetes mellitus least 3 month runin period HbA1c ≥7.0 % ≤10.0 % Type I diabetes mellitus , diabetes mellitus result pancreatic disorder , secondary diabetes mellitus Past current history severe diabetic complication Fasting plasma glucose &gt; 270 mg/dL treatment start History hereditary glucosegalactose malabsorption primary renal glucosuria Patients require insulin therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>TA-7284</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Sodium Glucose Co-transporter ( SGLT2 inhibitor )</keyword>
</DOC>